Latest news with #Penicillin-G
Time of India
7 days ago
- Business
- Time of India
Mobile production surges by 146% to ₹5.25 lakh crore in 4 fiscals, exports up 775%: Piyush Goyal
New Delhi: The production of mobiles in India in value terms has increased by around 146 per cent from ₹2,13,773 crore in FY 2020-21 to ₹5,25,000 crore in FY 2024-25, the Parliament was informed on Tuesday. During the same period, exports of mobile phones in value terms has increased by around 775 per cent from ₹22,870 crore in 2020-21 to ₹2,00,000 crore in 2024-25. The government's PLI and national industrial corridor schemes have incentivized domestic manufacturing, leading to increased production, job creation and a boost in exports, Commerce and Industry Minister Piyush Goyal , said in a written reply to a question in the Rajya Sabha. PLI Scheme has encouraged major smartphone companies to shift their production to India. As a result, India has become a major mobile phone manufacturing country. Due to the PLI scheme, there has also been a significant reduction in imports of raw materials in the pharma sector. Unique intermediate materials and bulk drugs are being manufactured in India including Penicillin-G, and transfer of technology has happened in manufacturing of Medical Devices such as (CT scan, MRI etc.). The PLI Scheme for White Goods is aimed at developing a robust component ecosystem for the Air Conditioners and LED Lights industry in India, with the goal of making the country an integral part of global supply chains. Following its launch, India has begun local production of key components such as compressors, copper tubes, heat exchangers, motors, and control assemblies for air conditioners, as well as LED chip packaging, drivers, engines, light management systems, and metallized films for capacitors in the LED segment. This shift is significantly reducing import dependency and strengthening domestic manufacturing capabilities, the minister further stated. The government has also launched Make in India 2.0 initiative which presently focuses on 27 sectors implemented across various ministries/departments and state governments. He further stated that the government has approved 12 new project proposals under the National Industrial Corridor Development Programme (NICDP) with total project cost of ₹28,602 crore to facilitate manufacturing investments into the country. Besides Atmanirbhar Bharat packages provide investment opportunities under National Infrastructure Pipeline and National Monetization Pipeline, India Industrial Land Bank, Industrial Park Rating System, soft launch of the National Single Window System etc. to promote manufacturing, the minister added.
Time of India
22-07-2025
- Business
- Time of India
Drug companies set for improved revenue growth in June quarter amid US market challenges
ET Intelligence Group: Select companies in the pharma and healthcare sector are expected to show improved revenue and profit for the June 2025 quarter driven by a strong growth in the domestic market. Some companies may face pricing pressure in the US market due to sequentially lower Revlimid sales, used for the treatment of myeloma (a type of blood cancer). The performance for hospital chains may improve driven by a jump in operational beds. Sun Pharmaceutical Industries ' revenue may grow in mid-single digit year-on-year, driven by market share gains in existing products. While the domestic business is expected to show traction, the US sales may moderate due to heightened competition in gRevlimid. Explore courses from Top Institutes in Select a Course Category Operations Management Leadership Data Science Others Degree MCA Finance Data Analytics MBA others Public Policy healthcare Digital Marketing Cybersecurity CXO Healthcare Management Project Management Design Thinking Technology Product Management PGDM Data Science Artificial Intelligence Skills you'll gain: Quality Management & Lean Six Sigma Analytical Tools Supply Chain Management & Strategies Service Operations Management Duration: 10 Months IIM Lucknow IIML Executive Programme in Strategic Operations Management & Supply Chain Analytics Starts on Jan 27, 2024 Get Details Dr Reddy's Laboratories domestic business is expected to grow on the back of rise in respiratory/derma segment. US revenue is highly dependent on the company's ability to book revenues through gRevlimid. Margin could decline slightly. Agencies Aurobindo Pharma 's revenue is expected to be modest on the back of decline in US sales. Penicillin-G plant's capacity utilisation improvement could drive the growth in future quarters. Margins are expected to be flattish. For Cipla , US sales are expected to decline due to a price fall for gRevlimid, slight sequential drop in inhaler sales, which may be partially offset by higher Lanreotide sales. Margins may decline by 80 basis points. Live Events Lupin 's revenue is expected to grow more than peers, driven by strong growth in the US business amid new launches and increased contribution from existing products. Margins are also expected to expand by around 800 basis points. Apollo Hospitals Enterprise may report double digit growth in revenue and profit amid stable occupancy and higher revenue per bed. In addition, Keimed, a pharma distribution company,which Apollo acquired in 2024 is likely to support the overall margin performance.
The Hindu
30-06-2025
- Business
- The Hindu
Aurobindo arm resumes Penicillin-G production after APPCB nod to operate fire-hit Kakinada plant
Aurobindo Pharma subsidiary Lyfius Pharma has resumed Penicillin-G production on receipt of Andhra Pradesh Pollution Control Board's go ahead to operate the Kakinada plant whose operations were paused after a fire in April. 'Lyfius, a wholly owned stepdown subsidiary, has re-started the production with immediate effect after receiving the consent to operate from APPCB on June 29,' the parent company said in a filing on Sunday. Following the fire incident on April 27, the company had said certain ancillary equipment were damaged and there was no impact to the core manufacturing infrastructure. 'As a precautionary measure and to facilitate necessary equipment replacements, operations at the plant will be temporarily paused for an estimated period of 20-25 days,' it had said. Last month, in an update, it said the preliminary assessment of loss is estimated around Rs.4 crore and Lyfius was in the process of submitting its final claim with the insurance company. It was also awaiting APPCB approval of the company's renewal application for 'consent to operate'.
Zawya
05-05-2025
- Business
- Zawya
Oman's pharmaceutical sector: A new pillar of national resilience
The pharmaceutical sector in Oman is fast becoming a critical component of national development—intersecting the goals of public health security, economic diversification, and industrial resilience. For decades, the country has relied heavily on pharmaceutical imports, with domestic production contributing only a small fraction of the total supply. However, in line with Vision 2040, the Sultanate of Oman is charting a new path—one focused on expanding local manufacturing, fostering investment, and integrating into global supply chains. Historically, the pharmaceutical industry in Oman has been modest in scale. As recently as 2020, only five domestic manufacturers operated in the country, meeting just 8 per cent of the market demand. The remainder—largely generic medicines, medical devices, and injectables—was sourced from abroad, costing the country over $500 million annually. But the situation is gradually shifting. Companies such as National Pharmaceutical Industries (NPI), established in 2001, have expanded their reach to over 50 countries and registered more than 600 products, setting a precedent for others to follow. The Omani government, recognising the strategic significance of the sector, has introduced a robust framework of incentives to support pharmaceutical manufacturing. This includes five-year tax exemptions, customs waivers on raw materials and machinery, and a 10 per cent price preference for local products in public tenders. These measures are designed not only to encourage investment but also to ensure a minimum level of domestic demand for locally produced medicines. Significantly, free zones such as Salalah and Suhar have become attractive sites for pharmaceutical development, offering modern infrastructure, proximity to petrochemical feedstock, and direct access to seaports. In Salalah, Philex Pharmaceuticals launched a major facility in 2023 with a projected investment of $150 million. The plant, spanning over 100,000 square metres, is capable of producing one billion capsules and tablets annually and marks Oman's entry into high-volume pharmaceutical manufacturing. Meanwhile, in Raysut, Dhofar Pharma began operations in late 2024, becoming the country's first facility to locally produce intravenous solutions and dialysis fluids. Built to international standards, the factory is designed to meet local demand and eventually export to regional markets such as the GCC and North Africa. Its capacity—15 million IV bags and over 2 million dialysis units per year—reflects both the scale of ambition and the urgent need for import substitution. Elsewhere, in Suhar Free Zone, Penicillin General Integrated is developing a factory to produce antibiotic raw materials like Penicillin-G and 6-APA. If successful, the plant could meet up to 10 per cent of global demand for these substances, positioning Oman as a strategic player in the global antimicrobial supply chain. In early 2025, the Ministry of Health also signed advance purchase agreements with six emerging Omani pharmaceutical firms to supply a range of products, including gene therapies, biologics, and surgical consumables. This move provides financial security for the manufacturers while aligning with national objectives for medicine self-sufficiency. Despite these advancements, significant challenges remain. First is the continued dependence on imported raw materials and finished drugs, particularly from India, China, and Europe. This reliance makes Oman vulnerable to global supply chain disruptions—a lesson underscored by the COVID-19 pandemic. Moreover, the country's R&D ecosystem is still in its infancy, limiting its ability to innovate or develop proprietary medicines. Human capital is another pressing issue. The pharmaceutical industry requires highly specialised professionals—pharmacists, chemists, and engineers. While Omanisation is a long-term goal, many positions are currently held by expatriates. Companies like Dhofar Pharma aim to achieve 80 per cent local employment within five years, but doing so will require deeper collaboration between academia and industry. Additionally, the high cost of local manufacturing presents a barrier to competitiveness. International firms benefit from economies of scale that drive down unit costs—something Oman is still working towards. Without ongoing government support and incentives, local manufacturers may struggle to compete on price in both domestic and export markets. Nonetheless, the opportunities are considerable. The GCC region spends billions on pharmaceutical imports each year, and Oman's geographic location, coupled with free trade agreements and world-class ports, gives it a logistical edge. If supply chains can be made more integrated and efficient, Oman could serve as a manufacturing and re-export hub for the wider region. International partnerships will be key to accelerating progress. A recent example is the strengthening of ties with Algeria, which has achieved 75 per cent pharmaceutical self-sufficiency. During a high-level visit in early 2025, Omani and Algerian officials explored opportunities for joint ventures, technology transfer, and mutual market access. Such collaborations offer a strategic shortcut to building local capacity while enhancing product credibility. Oman's pharmaceutical ambitions are not without hurdles, but the foundation is solid. With a supportive policy environment, growing industrial investment, and clear political will, the country is well-positioned to make the sector a cornerstone of its future economy. What is needed now is persistence—investment in people, in research, and in international collaboration. If these elements continue to align, Oman could, within a decade, become a regional leader in pharmaceutical production, contributing not only to economic growth but also to national resilience in the face of global uncertainty. 2022 © All right reserved for Oman Establishment for Press, Publication and Advertising (OEPPA) Provided by SyndiGate Media Inc. (
Observer
03-05-2025
- Business
- Observer
Oman's pharmaceutical sector: A new pillar of national resilience
The pharmaceutical sector in Oman is fast becoming a critical component of national development—intersecting the goals of public health security, economic diversification, and industrial resilience. For decades, the country has relied heavily on pharmaceutical imports, with domestic production contributing only a small fraction of the total supply. However, in line with Vision 2040, the Sultanate of Oman is charting a new path—one focused on expanding local manufacturing, fostering investment, and integrating into global supply chains. Historically, the pharmaceutical industry in Oman has been modest in scale. As recently as 2020, only five domestic manufacturers operated in the country, meeting just 8 per cent of the market demand. The remainder—largely generic medicines, medical devices, and injectables—was sourced from abroad, costing the country over $500 million annually. But the situation is gradually shifting. Companies such as National Pharmaceutical Industries (NPI), established in 2001, have expanded their reach to over 50 countries and registered more than 600 products, setting a precedent for others to follow. The Omani government, recognising the strategic significance of the sector, has introduced a robust framework of incentives to support pharmaceutical manufacturing. This includes five-year tax exemptions, customs waivers on raw materials and machinery, and a 10 per cent price preference for local products in public tenders. These measures are designed not only to encourage investment but also to ensure a minimum level of domestic demand for locally produced medicines. Significantly, free zones such as Salalah and Suhar have become attractive sites for pharmaceutical development, offering modern infrastructure, proximity to petrochemical feedstock, and direct access to seaports. In Salalah, Philex Pharmaceuticals launched a major facility in 2023 with a projected investment of $150 million. The plant, spanning over 100,000 square metres, is capable of producing one billion capsules and tablets annually and marks Oman's entry into high-volume pharmaceutical manufacturing. Meanwhile, in Raysut, Dhofar Pharma began operations in late 2024, becoming the country's first facility to locally produce intravenous solutions and dialysis fluids. Built to international standards, the factory is designed to meet local demand and eventually export to regional markets such as the GCC and North Africa. Its capacity—15 million IV bags and over 2 million dialysis units per year—reflects both the scale of ambition and the urgent need for import substitution. Elsewhere, in Suhar Free Zone, Penicillin General Integrated is developing a factory to produce antibiotic raw materials like Penicillin-G and 6-APA. If successful, the plant could meet up to 10 per cent of global demand for these substances, positioning Oman as a strategic player in the global antimicrobial supply chain. In early 2025, the Ministry of Health also signed advance purchase agreements with six emerging Omani pharmaceutical firms to supply a range of products, including gene therapies, biologics, and surgical consumables. This move provides financial security for the manufacturers while aligning with national objectives for medicine self-sufficiency. Despite these advancements, significant challenges remain. First is the continued dependence on imported raw materials and finished drugs, particularly from India, China, and Europe. This reliance makes Oman vulnerable to global supply chain disruptions—a lesson underscored by the COVID-19 pandemic. Moreover, the country's R&D ecosystem is still in its infancy, limiting its ability to innovate or develop proprietary medicines. Human capital is another pressing issue. The pharmaceutical industry requires highly specialised professionals—pharmacists, chemists, and engineers. While Omanisation is a long-term goal, many positions are currently held by expatriates. Companies like Dhofar Pharma aim to achieve 80 per cent local employment within five years, but doing so will require deeper collaboration between academia and industry. Additionally, the high cost of local manufacturing presents a barrier to competitiveness. International firms benefit from economies of scale that drive down unit costs—something Oman is still working towards. Without ongoing government support and incentives, local manufacturers may struggle to compete on price in both domestic and export markets. Nonetheless, the opportunities are considerable. The GCC region spends billions on pharmaceutical imports each year, and Oman's geographic location, coupled with free trade agreements and world-class ports, gives it a logistical edge. If supply chains can be made more integrated and efficient, Oman could serve as a manufacturing and re-export hub for the wider region. International partnerships will be key to accelerating progress. A recent example is the strengthening of ties with Algeria, which has achieved 75 per cent pharmaceutical self-sufficiency. During a high-level visit in early 2025, Omani and Algerian officials explored opportunities for joint ventures, technology transfer, and mutual market access. Such collaborations offer a strategic shortcut to building local capacity while enhancing product credibility. Oman's pharmaceutical ambitions are not without hurdles, but the foundation is solid. With a supportive policy environment, growing industrial investment, and clear political will, the country is well-positioned to make the sector a cornerstone of its future economy. What is needed now is persistence—investment in people, in research, and in international collaboration. If these elements continue to align, Oman could, within a decade, become a regional leader in pharmaceutical production, contributing not only to economic growth but also to national resilience in the face of global uncertainty. Qasim Al Maashani The writer is the head of business and politics section at Oman Observer
